188 related articles for article (PubMed ID: 15801830)
21. Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.
Tsou HR; Liu X; Birnberg G; Kaplan J; Otteng M; Tran T; Kutterer K; Tang Z; Suayan R; Zask A; Ravi M; Bretz A; Grillo M; McGinnis JP; Rabindran SK; Ayral-Kaloustian S; Mansour TS
J Med Chem; 2009 Apr; 52(8):2289-310. PubMed ID: 19317452
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antiproliferative activity in vitro of new 2-, 3- or 4-substituted pyrido[2',3':3,4]pyrazolo[1, 5-a]pyrimidines.
Poreba K; Wietrzyk J; Opolski A
Acta Pol Pharm; 2006; 63(3):189-94. PubMed ID: 20085223
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Workman P; Waterfield MD; Parker P
Bioorg Med Chem Lett; 2007 May; 17(9):2438-42. PubMed ID: 17339109
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
Murphy ST; Alton G; Bailey S; Baxi SM; Burke BJ; Chappie TA; Ermolieff J; Ferre R; Greasley S; Hickey M; Humphrey J; Kablaoui N; Kath J; Kazmirski S; Kraus M; Kupchinsky S; Li J; Lingardo L; Marx MA; Richter D; Tanis SP; Tran K; Vernier W; Xie Z; Yin MJ; Yu XH
J Med Chem; 2011 Dec; 54(24):8490-500. PubMed ID: 22040023
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of 2,4,6-functionalized derivatives of pyrido[2,3-d]pyrimidines as cytotoxic agents and apoptosis inducers.
Sanmartín C; Domínguez MV; Cordeu L; Cubedo E; García-Foncillas J; Font M; Palop JA
Arch Pharm (Weinheim); 2008 Jan; 341(1):28-41. PubMed ID: 18161903
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
31. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
32. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
[TBL] [Abstract][Full Text] [Related]
33. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
34. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest.
Fares M; Abou-Seri SM; Abdel-Aziz HA; Abbas SE; Youssef MM; Eladwy RA
Eur J Med Chem; 2014 Aug; 83():155-66. PubMed ID: 24956552
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
[TBL] [Abstract][Full Text] [Related]
37. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
Sotillo R; Renner O; Dubus P; Ruiz-Cabello J; Martín-Caballero J; Barbacid M; Carnero A; Malumbres M
Cancer Res; 2005 May; 65(9):3846-52. PubMed ID: 15867383
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, SAR study and biological evaluation of novel pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as anti-proliferative agents.
Wang YD; Honores E; Wu B; Johnson S; Powell D; Miranda M; McGinnis JP; Discafani C; Rabindran SK; Cheng W; Krishnamurthy G
Bioorg Med Chem; 2009 Mar; 17(5):2091-100. PubMed ID: 19200741
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
[TBL] [Abstract][Full Text] [Related]
40. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
